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ABSTRACT
Umbilical cord blood (UBC) stem cells are a useful stem cell source for patients without matched related or
unrelated donors. Adult transplantation with single UBC units is associated with high transplantation-related
mortality (TRM). In most cases, mortality is due to infection related to slow engraftment and immunoincom-
petence. In this study, we used a reduced-intensity conditioning regimen of fludarabine, melphalan, and
antithymocyte globulin followed by 2 partially matched UBC units. The UBC units were a 4/6 HLA match or
better with each other and with the patient and achieved a minimum precryopreservation cell dose of 3.7 107
nucleated cells/kg. A total of 21 patients (median age, 49 years) were treated. The median time to an absolute
neutrophil count > 0.5  109/L was 20 days, and the median time to an unsupported platelet count > 20 
109/L was 41 days. Two patients experienced primary graft failure and underwent a second UBC transplan-
tation. One patient had a late graft failure. Acute graft-versus-host disease (GVHD) grade II-IV occurred in
40% of patients. The 100-day TRM was 14%, and the 1-year disease-free survival was 67%. Mixed chimerism
was associated with a higher risk of chronic GVHD. Our findings indicate that adult patients can tolerate
double UBC transplantation well and achieve sustained antitumor responses using this reduced-intensity
conditioning regimen.
© 2007 American Society for Blood and Marrow Transplantation
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iNTRODUCTION
Umbilical cord blood (UCB) has been shown to
ontain sufﬁcient progenitor cells to provide durable
ngraftment in children, and it provides an alternative
tem cell source for patients without matched related
r unrelated donors [1,2]. Trials of UCB transplanta-
ion in children have shown a 30%-80% disease-free
urvival (DFS), depending on patient age and disease
tatus [3,4]. However, in adults, the results of single
CB transplantation have been less promising be-
ause of high transplantation-related mortality due to
low infused cell dose and the subsequent risk of
nfection associated with prolonged cytopenia [5-7].
The results of both pediatric and adult UBC trans-
lantation studies suggest improved survival with
BC grafts of higher cell dose [3,4,8]. Barker and
olleagues reported that outcomes may be improved
ith 2 UBC units in both the nonmyeloablative and i
2blative setting [9,10]. Preliminary data from the same
roup indicates a reduction in relapse with transplan-
ation of 2 UBC units [11]. In an effort to increase the
ell dose and decrease transplantation-related toxicity,
e treated 21 patients with a reduced-intensity con-
itioning regimen followed by sequential infusion of 2
artially matched UBC units.
ATIENTS AND METHODS
atients
Patients were eligible for UCB transplant if they
ad no 5/6 or 6/6 HLA-A, -B, or -DR allele-matched
elated donor or no 6/6 HLA-A, -B, or -DR allele-
atched unrelated donor available. Patients were age
8-65 years and met standard transplantation eligibil-
ty criteria, including ejection fraction  45%, diffus-
ng capacity of the lung for carbon monoxide  50%
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Double Cord Blood Transplantation 83redicted, and European Cooperative Oncology
roup performance status of 0-2. Patients with acute
eukemia were eligible if they were in second or sub-
equent complete remission or in ﬁrst remission with
igh-risk cytogenetics or an antecedent hematologic
isorder. Patients with refractory leukemia or leuke-
ia in relapse were not eligible. Patients with chronic
ymphocytic leukemia progressive after at least 2 che-
otherapy regimens, myelodysplasia with life-threat-
ning cytopenia, aplastic anemia, and non-Hodgkin’s
ymphoma or Hodgkin’s lymphoma refractory to che-
otherapy or relapse were eligible. We limited our
tudy to a reduced-intensity conditioning regimen,
ecause it was anticipated that the lower risk of mu-
ositis would be preferable in patients with a high
robability for delayed engraftment. The protocol was
eviewed and approved by the Institutional Review
oard of the Dana-Farber/Harvard Cancer Center.
ritten informed consent was obtained from all pa-
ients before participation.
LA Typing
Conﬁrmatory HLA typing was performed on all
CB units before transplantation. Molecular typing
as performed for both class I (HLA-A, -B, -C) and
lass II (HLA-DR and -DQ) alleles. Information was
ecorded on all of these alleles, but only HLA-A, -B,
nd -DR were used in the search strategy. HLA typing
as performed by polymerase chain reaction and se-
uence-speciﬁc primer technology (One Lambda, Ca-
oga Park, CA).
BC Unit Selection
UCB units were obtained from a various national
nd international registries. UBC units had to meet a
inimum combined precryopreservation cell dose of
.7  107 nucleated cells/kg recipient. A minimum
ell dose per UCB unit was not required. UCB units
ere required to be a 4/6 or better allele-level
LA-A, -B, and -DR match with each other and with
he patient. Typing at HLA-C and -DQ was obtained
ut not used in the match strategy. The choice of
CB when multiple units were available was based on
igher cell dose and greater HLA compatibility, in
hat order.
reatment Plan
Patients received conditioning with ﬂudarabine 30
g/m2/day on days 8 through 3 (total dose, 180
g/m2), melphalan 100 mg/m2/day on day 2, and
abbit antithymocyte globulin (Sangstat, Fremont,
A) 1.5 mg/kg/day on days7,5,3, and1 (total
ose, 6.0 mg/kg). GVHD prophylaxis consisted of
ontinuous intravenous infusion cyclosporine starting
n day 3 and mycophenolate mofetil (MMF) 15
g/kg intravenously twice daily starting on day 0. syclosporine and MMF were given orally when the
atient was able to tolerate oral medications. In the
bsence of GVHD, the MMF was tapered between
ays 30 and 60 posttransplantation, and the cyclo-
porine was tapered between days 100 and 180.
tem cells were infused on day 0. UCB units were
hawed according to the methods of Rubinstein et al
12], and administered sequentially on the same day
-6 hours apart. After transplantation, patients re-
eived supportive care with transfusion support; pro-
hylactic antibacterial, antifungal, antiviral, and anti-
neumocystis therapy; and ﬁlgrastim 5 g/kg/day
rom day 5 until the absolute neutrophil count was
2.0 109 cells/L for 2 consecutive days. Neutrophil
ngraftment was deﬁned as the ﬁrst of 3 consecutive
ays with neutrophil recovery to at least 0.5  109
ells/L. Platelet engraftment was deﬁned as the ﬁrst
ay of an unsupported platelet count  20  109
ells/L (no platelet transfusion within 7 days). Early
raft failure was deﬁned as absence of neutrophil re-
overy by day 35 after transplantation. Late graft
ailure was deﬁned as the presence of neutrophil en-
raftment by day 35, followed by a decline of the
eutrophil count to 0.5 109 cells/L after day42,
nd the loss of donor chimerism. GVHD was graded
ccording to the consensus criteria [13].
onor Chimerism Analysis
Donor chimerism was determined from the pe-
ipheral blood at posttransplantation weeks 2, 4, 6, 8,
0, and 12 and months 6, 12, and 24. Bone marrow
amples were also obtained at posttransplantation
onths 3, 6, 12, and 24. Chimerism assays were per-
ormed by short tandem repeat analysis using a mul-
iplex kit with primers for 10 different loci (Proﬁler
lus, Applied Biosystems, Foster City, CA) and an
pplied Biosystems ABI-310 genetic analyzer. Pre-
ransplantation samples from the recipient and both
BC donors were tested to identify alleles at each
ocus that would be speciﬁc for each of them. When
ossible, recipient blood was tested with unseparated
ells as well as CD3- and CD33-enriched popula-
ions, separated using a negative selection assay (Ro-
etteSep; StemCell Technologies, Vancouver, Can-
da) [14].
tatistical Analysis
Time for the engraftment and survival outcomes
as measured from day 0 of stem cell infusion and
stimated by the Kaplan-Meier method. The engraft-
ent time of a hematopoietic parameter was censored
t the time of relapse, or time of death if the event
ccurred before engraftment. Patients who had not
ied were censored at their last follow-up date in the
nalysis of overall survival (OS). Patients who were
till alive without relapse were censored at the same
t
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K. K. Ballen et al.84ime with respect to DFS. Wilcoxon’s rank-sum test
as used to determine the association between CD4
ount at day 100 and likelihood of infection. Mc-
emar’s test and Wilcoxon’s signed-rank test were
sed to identify UBC factors associated with the pre-
ominating unit at day 100 among the evaluable
atients, excluding primary graft failures and early
eaths during the ﬁrst month posttransplantation.
he rates of acute grade II-IV GVHD and chronic
VHD were analyzed actuarially, treating graft fail-
re and non-GVHD death as independent competing
isks. The log-rank test was used to compare OS and
VHD incidence between groups. All P values were
ased on 2-sided hypothesis tests, with the exact in-
erence computed using StatXact Version 6 (Cytel
oftware Corp, Cambridge, MA).
BC Search
During the study period, UBC searches were un-
ertaken for 60 patients, who lacked a suitably
atched related or unrelated donor. In 48 patients
80%), the searches resulted in identiﬁcation of an
ppropriate matched pair. Twenty-seven patients did
ot proceed to reduced-intensity double UBC trans-
lantation because another donor source was identi-
ed, the patient elected not to undergo transplanta-
ion, the disease relapsed, or insurance approval could
ot be obtained. UBC searches were unsuccessful for
2 patients; 9 of these patients were non-Caucasian.
ive patients would have had 4/6 UBC matches if
ntigen level, rather than allele-level matching, were
sed for class I. The median number of conﬁrmatory
estings performed to locate a suitable UBC pair was
(range, 2-37).
ESULTS
atient Characteristics
Patient characteristics are listed in Table 1. A total
f 21 patients (median age, 49 years) underwent trans-
lantation in this study between October 2003 and
ay 2005. The median recipient weight was 78 kg
range, 58-111 kg). Four patients were non-Cauca-
ian. Acute myelogeneous leukemia was the most
ommon diagnosis. Five patients (24%) had under-
one previous autologous stem cell transplantation.
raft Characteristics
Characteristics of the UBC graft are displayed in
able 2. Allele-level typing for HLA-A, -B, and -DR
ere used in the matching strategy. Fourteen patients
67%) received 2 4/6 matched UBC units, 5 patients
eceived 1 4/6 and 1 5/6 HLA-matched unit, and 2
atients received 2 5/6 matched units. Most of the
BC pairs (76%) were 4/6 matches. Allele-level typ-ng for HLA-C and -DQ were performed for 15 tatients and corresponding UBC pairs and are dis-
layed in Table 2. Matching ranged from 8/10 alleles
o 5/10 alleles for patients and UBC units, and 10/10
o 5/10 alleles between UBC units; for example, 4/6
LA-A, -B, and -DR allele matches corresponded to
/10, 6/10, or 7/10 HLA-A, -B, -C, -DR, and -DQ
llele matches. The median infused cell doses were 4.0
107 nucleated cells/kg (range, 2.9-5.1) and 1.9 
05 CD34 cells/kg (range, 0.6-9.7) for the 2 UBC
nits combined. The median infused cell doses for
ach individual UBC unit were 2.0  107 nucleated
ells/kg (range, 1.1-3.4) and 0.9 105 CD34 cells/kg
range, 0.1-8.6).
ngraftment and GVHD
Two patients had primary graft failure and re-
eived a second double UBC transplant with a differ-
nt conditioning regimen of low-dose total body ra-
iation, cyclophosphamide, and ﬂudarabine on days
39 and 50 after the ﬁrst transplantation. Both of
hese patients had aplastic anemia with late transfor-
ation to myelodysplastic syndrome after failing to
espond to antithymocyte serum and calcineurin in-
ibitor therapy. Neither had received previous cyto-
oxic therapy. Before the second transplantation, the
atients remained neutropenic and thrombocytope-
ic, with no evidence of autologous reconstitution.
ne patient died of zygomycetes infection 8 months
fter the ﬁrst transplantation, and the other patient
as surviving at 19 months after the ﬁrst transplanta-
ion. Among the remaining 19 patients, the median
able 1. Patient characteristics
Median Range
ge (years) 49 24-63
eight (kg) 78 58-111
ime from diagnosis to
transplantation (months) 22 4-106
ex (n)
Male 15
Female 6
iagnosis (n)
Acute myeloid leukemia
8 (4 CR1, 4 CR2
and greater)
Acute lymphocytic leukemia 1 (CR1)
Myelodysplastic syndrome 1
Chronic lymphocytic leukemia 2
Non-Hodgkin’s lymphoma 5 (2 CR2, 3 PR)
Hodgkin’s lymphoma 2
Aplastic anemia 2
ace/ethnicity
White, non-Hispanic 17
White, Hispanic 2
Black 1
Asian 1
revious autologous
transplantation 5ime to an absolute neutrophil count  0.5  109
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Double Cord Blood Transplantation 85ells/L was 20 days (range, 15-34 days). Two patients
id not recover to a platelet count 100 109 cells/L
y day 100. Among the remaining patients, the me-
ian time to a platelet count  20  109 cells/L
nsupported was 41 days (range, 21-55 days), and the
edian time to a platelet count  100  109 cells/L
as 63 days (range, 34-91 days). One patient experi-
nced late graft failure 3 months posttransplanta-
ion, after a rapid early taper of cyclosporine in the
ontext of severe adenovirus infection. He under-
ent infusion of previously stored autologous stem
ells at 4 months posttransplantation and relapsed
8 months posttransplantation. Acute GVHD grade
-IV was seen in 58% of patients (40% grade II-IV),
ut only 1 patient had grade III GVHD and no
atients had grade IV GVHD. There were no
eaths attributable to acute GVHD. Sixteen pa-
ients were evaluable for chronic GVHD; 5 of these
able 2. Cord blood characteristics
n %
llele-level HLA match (-A, -B, -DR) patient
and cords
4/6, 4/6 14 67
4/6, 5/6 5 24
5/6, 5/6 2 10
llele-level HLA match (-A, -B, -DR) cord
and cord
4/6 16 76
5/6 3 14
6/6 2 10
llele-level HLA match (-A, -B, -C, -DR, -DQ)
patient and cords
8/10, 8/10 1 5
8/10, 6/10 1 5
7/10, 7/10 2 10
7/10, 6/10 5 24
6/10, 6/10 3 14
6/10, 5/10 3 14
LA-C and -DQ Not available 6 29
llele-level HLA match (-A, -B, -C, -DR, -DQ)
cord and cord
10/10 2 10
8/10 2 10
7/10 3 14
6/10 7 33
5/10 1 5
LA-C and -DQ not available 6 29
Median Range
ombined cell doses/kg
Total nucleated cells prethawing  107 4.8 3.5-7.2
Total nucleated cells infused  107 4.0 2.9-5.1
Total CD34 cells infused  105 1.9 0.6-9.7
redominating UBC unit cell doses/kg
Total nucleated cells infused  107 2.2 1.6-3.4
CD34 cells infused  105 1.1 0.3-8.6
onpredominating UBC unit cell doses/kg
Total nucleated cells infused  107 1.8 1.1-2.7
Total CD34 cells infused  105 0.7 0.1-6.66 patients developed chronic GVHD, 2 with ex- tensive disease. There was 1 death from chronic
VHD complicated by vancomycin-resistant en-
erococcus (VRE) sepsis.
elapse and Survival
Transplantation-related (nonrelapse) mortality
as 14% at 100 days and 19% at 6 months. One
atient with CLL had progressive disease and 2 pa-
ients (1 with AML as discussed above and 1 with
HL) relapsed. The median follow-up of survivors
as 18 months (range, 11-30 months). OS was 71%
nd DFS was 67%, as illustrated in Figure 1. The
rojected 2-year OS and DFS are 71% and 55%,
espectively. Causes of death occurring before day
100 included central nervous system hemorrhage,
taphylococcal sepsis with cerebral edema, and post-
ransplantation lymphoproliferative disease. There
ere 3 deaths after day 100, 1 from chronic GVHD
ith VRE sepsis, 1 from disseminated fungal infection
fter a second double UBC transplantation in a patient
igure 1. OS for all patients undergoing sequential UBC trans-
lantation (A) and DFS for all patients undergoing sequential UBC
ransplantation (B).
w
t
i
s
6
I
f
d
d
c
g
T
p
B
h
c
l
p
n
C
d
w
U
c
f
p
d
p
p
w
w
a
b
4
1
a
s
b
U
ﬁ
t
n
.
u
0
c
a
c
i
b
P
c
t
a
b
ﬁ
n
p
r
p
t
h
N
p
t
o
U
T
n
a
i
o
f
c
a
G
1
h
u
F
b
T
C
C
C
C
N
K. K. Ballen et al.86ith primary graft failure, and 1 from posttransplan-
ation lymphoproliferative disorder. Other nonfatal
nfections included cytomegalovirus reactivation, dis-
eminated adenovirus, mucor, and human herpes virus
encephalitis.
mmune Reconstitution
Peripheral blood was analyzed by ﬂow cytometry
or T-cell, B-cell, and natural killer cell markers at 100
ays and 1 year posttransplantation; the results are
isplayed in Table 3. Early graft failures were ex-
luded from these analyses, and the patient with late
raft failure was excluded from the 1-year analysis.
he median total CD4 count at 100 days posttrans-
lantation was 90 cells/L (range, 18-425 cells/L).
y 1-year posttransplantation, the median CD4 count
ad risen to 518 cells/L (range, 21-1785 cells/L),
onsistent with immune system recovery. Severe and
ife-threatening infections were more common in the
atients with a lower CD4 count at day 100 but did
ot reach statistical signiﬁcance.
himerism Data
Excluding the 2 early graft failures and 2 early
eaths within 1 month of transplantation, chimerism
as evaluable in 17 patients. By day 28, a single
BC unit predominated in 8 patients. In 6 patients, a
ombination of both UBC units was detected, ranging
rom 50%5–0% to 80%–20%. Three patients had
ersistent host hematopoiesis; 2 of these patients had
etectable donor cells from only 1 UBC unit. Three
atterns of chimerism emerged by 12 weeks posttrans-
lantation (Fig 2). Group 1 comprised 10 patients
ith evidence of only a single UBC engraftment by 6
eeks posttransplantation; the same pattern was seen
t week 12. Group 2 comprised 4 patients in whom
oth UBC donors were initially identiﬁed, but in 3 of
patients, only a single donor predominated by week
2. In the other patient, both donors were present in
69/31 ratio at week 12. Group 3 (3 patients) con-
isted of patients with a mixed chimera of recipient
lood and a single UBC unit.
In 76% of patients (13 of 17), the predominant
able 3. Immune reconstitution after UCB transplantation
Day  100 (n  11) Year  1 (n  11)
Median Range Median Range
D4 90 (18-425) 518 (21-1785)
D4/CD8 3.4 (0.23-27.0) 2 (0.1-31.0)
D1656 269 (34-764) 228 (105-2190)
D19 360 (0-4458) 614 (0-1088)
umbers of cells/L obtained from peripheral blood ﬂow cytom-
etry are expressed as the median and range; n refers to the
number of patient samples analyzed.BC unit at 3 months posttransplantation was the erst UBC unit infused (P  .049). There was a trend
oward the predominant UBC unit having a higher
ucleated cell dose (P  .071) and CD34 count (P 
120). The median cell doses of the predominant UBC
nit were higher than those of the minor UBC unit by
.4  107 nucleated cells/kg and 0.3  105 CD34
ells/kg. A closer HLA match, ABO match, or sex
greement did not correlate with the predominant
ord. Some ninety percent of the UBC unit pairs were
nfused 3.5-4.5 hours apart. There was no correlation
etween time between unit infusions and graft failure.
REDICTORS FOR SURVIVAL AND GVHD
Patient age, HLA match, cell doses infused, and
himerism pattern at day 100 were analyzed to de-
ermine predictive factors for OS and DFS, as well as
cute GVHD (grade II-IV) and chronic GVHD (Ta-
le 4). The limited patient numbers precluded the
tting of a multivariate model; thus, the univariate
umbers must be interpreted cautiously. At 1 year
osttransplantation, DFS was 44% and OS was 56%
espectively for patients over age 50 (n  9). Younger
atients achieved 83% DFS and OS. There was a
rend toward improved survival in patients with a
igher CD34 count in the predominant UBC unit.
o patients have died among those who received a
redominant UBC unit with a CD34 dose/kg above
he median of 1.9  105. A higher nucleated cell dose
r closer HLA match between the patient and the 2
BC units was not associated with better survival.
he HLA match of the predominating UBC unit did
ot correlate with survival or with GVHD. There was
trend toward less chronic GVHD in the patients
nfused with lower CD34 doses; however, there were
nly 5 patients with chronic GVHD, and the median
ollow-up of the study is 18 months. In addition, the
himerism pattern (chimerism groups 2 and 3) was
lso strongly associated with the presence of chronic
VHD. The actuarial rate of chronic GVHD rate at
year posttransplantation was 100% in patients who
ad mixed chimera of either 2 UBC units or 1 UBC
nit and recipient blood at 6 weeks posttransplanta-
Week 12 Chimerism
0%
20%
40%
60%
80%
100%
1 2 3
Group
%
 H
em
at
op
oi
es
is
Recipient
Loser
Winner
igure 2. Chimerism studies: emergence of 3 patterns of chimerism
y week 12. The bars represent mean percent hematopoiesis for
ach group.
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Double Cord Blood Transplantation 87ion, but 0% in patients who had evidence of only 1
ord engraftment (P  .001). The strong association
etween chimerism and GVHD remained highly sig-
iﬁcant even after adjusting for potential confounding
y each of the factors in Table 4. However, these
umbers should be interpreted cautiously, given the
mall number of patients with chronic GVHD.
ISCUSSION
In this study, we report a low TRM and encour-
ging DFS using a reduced-intensity regimen fol-
owed by sequential UBC transplantation. These
ndings are consistent with the favorable experi-
nces of nonmyeloablative and reduced-intensity
egimens after related and unrelated adult donor
ransplantation [15-17]. Reduced-intensity regi-
ens have been used with single UBC transplanta-
ion; however, TRM was high even with a reduced-
ntensity regimen [18,19].
The sequential or double UBC transplantation
pproach was built on the observation that cell dose is
n important prognostic factor for engraftment and
urvival [6,20]. An early report of patients infused with
ultiple mismatched units suggested that crossed im-
unologic rejection would not occur [21]. Moreover,
ecent studies by Barker et al [9] at the University of
innesota demonstrated that reliable engraftment
an occur using 2 UCB products.
In our study, the 100-day TRM was remarkably
ow, at 14%. The low TRM might be attributable to
atient selection (patients with active leukemia were
xcluded), high infused cell dose (all patients re-
eived 2 UBC units, with a median nucleated cell
ose of 4.0  107 cells/kg), allele-level matching, and
low incidence of GVHD disease. Younger patients
ad a better outcome than patients over age 50. Be-
ause there are no objective data demonstrating better
utcomes for myeloablative therapy in UBC trans-
lantation, we chose to focus our attention on re-
able 4. Univariate predictors for survival and GVHD
Patient and UCB factors
ge: < 50 vs >50 years
otal infused nucleated cells/kg: < vs > 4.0  107
otal infused CD34 cells/kg: < vs >1.9  105
redominating cord nucleated cells/kg: < vs > 2.15  107
redominating cord CD34 cells/kg: < vs >1.0  105
LA-A, -B, -DR patient–cord: > 4/6,4/6 vs 4/6,4/6
LA-A, -B, -DR cord–cord: 5/6,6/6 vs 4/6
LA A,B,C,DR,DQ patient–cord: >6/10,6/10 vs 6/10,6/10
LA-A, -B, -C, -DR, -DQ cord–cord: >6/10 vs 6/10
himerism day 100: group 1 vs groups 2 and 3
GHVD, acute graft-versus-host disease; cGHVD, chronic graft-vuced-intensity transplantation, because it was antic-pated that the lower incidence of mucositis would be
referable in patients with a high probability of having
rolonged neutrophil nadirs.
The relapse rate was low, suggesting preservation
f the graft-versus-leukemia after UBC transplanta-
ion. The 2 patients with graft failure had aplastic
nemia/MDS and had not received previous cytotoxic
hemotherapy. Each had primary graft failure but
ngrafted satisfactorily after the subsequent adminis-
ration of a more intensive conditioning regimen, fol-
owed by a second double UBC transplant. We have
reviously shown that lack of previous intensive ther-
py is a risk factor for graft failure in nonmyeloablative
nrelated transplants or related donor transplants with
ery-low-dose conditioning [22,23]. Two patients
ied of posttransplantation lymphoproliferative disor-
er (PTLD), on days 41 and 216 posttransplantation.
n both of these patients, recurrent disease was sus-
ected, and posttransplantation lymphoma was diag-
osed late in the course. The greater immunosuppres-
ive activity of thymoglobulin may also be a contributing
actor to the PTLD seen in our study.
Future studies include monthly Epstein-Barr virus
EBV) monitoring. The risk of EBV viremia or EBV
osttransplantation lymphoproliferative disorder has
een reported to be 20% in UBC recipients condi-
ioned with nonmyeloablative regimens containing
ntithymocyte globulin and 7% in UBC recipients
onditioned with an ablative regimen containing an-
ithymocyte globulin [24]. The median time to devel-
pment of PTLD was 133 days, and 5 of 9 patients
ith PTLD survived.
In all of our patients, chimerism analyses indicated
he predominance of 1 cord by 3 months posttrans-
lantation. Patients who were mixed chimeras at 6
eeks posttransplantation had a higher incidence of
eveloping chronic GVHD. The explanation for this
bservation is unclear; a hypothesis may be ongoing
raft-versus-graft interactions. This ﬁnding will need
o be conﬁrmed in larger trials.
P values
OS aGVHD cGVHD
.165 .991 0.073
.149 .969 .537
.635 .385 .106
1.000 .995 .504
.082 .269 .160
.378 .538 .577
.553 .343 .862
.420 .688 .303
.928 .969 .859
.537 .347 <.001
ost disease.In our series, with a limited number of patients,
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K. K. Ballen et al.88he ﬁrst UBC unit infused was more often the chi-
erism “winner.” One possible explanation for this is
hat there may be limited opportunities to ﬁll the
ematopoietic stem cell niche after conditioning, and
hat the ﬁrst UBC infused may be more likely to ﬁll
his niche [25]. Scadden et al have demonstrated that
he capacity of the stem cell niche is limited; in a
urine system, osteoblastic cells form a regulatory
omponent of the stem cell niche [26], and the osteo-
last product, osteopontin, may provide a constraint
gainst stem cell numbers in this niche [27]. Also in a
urine model, Nilsson has shown that nonlineage-
ommitted hematopoetic stem cells redistributed to
he endosteal hematopoietic niche region by 4 hours
28]. Our UCB units were infused 1-6 hours apart,
ith most units infused 4 hours apart. It is possible
hat in a competitive niche repopulation model, even
short interval (2-4 hours) may be sufﬁcient to confer
n advantage to the ﬁrst infused unit. The Minnesota
roup did not report this ﬁnding; however, in that
nalysis, UBC units were administrated directly after
ne another, which may not have allowed sufﬁcient
ime for the ﬁrst unit to populate the niche [9,10].
hese observations need to be tested in a larger pa-
ient population.
Our study is the ﬁrst double UBC study to care-
ully evaluate high-resolution HLA typing and match-
ng between the 2 UBC units. Preliminary data using
ntigen-level typing for class I suggest higher posten-
raftment mortality in mismatched UBC transplanta-
ion recipients [29]. The use of allele-level typing has
esulted in improved outcomes in the unrelated
one marrow transplantation setting compared with
ntigen-level typing [30]. Therefore, selected UBC
roducts had to be a 4/6 HLA-A, -B, and -DR
llele-level match or better with each other and with
he patient. There was no obvious relationship be-
ween the degree of histocompatibility between the
atient and UBC units and the risk of acute or
hronic GVHD, but small numbers limited the abil-
ty to detect such a relationship. Mismatching at
LA-C has been associated with worse outcomes
fter adult unrelated-donor reduced-intensity trans-
lantation [31]. HLA-C and -DQ typing were ob-
ained but were not used in the matching strategy.
n the UBC setting, the use of allele-level typing
ay have limited the degree of mismatch and ex-
luded 5 patients from transplantation. In contrast,
he NETCORD group did not ﬁnd a beneﬁt of
igh-resolution typing for HLA-A, -B, -C, -DR,
nd -DQ in single UBC transplantation outcomes
32]. Although allele-level matching might not be
mportant for single UBC transplantation, allele-
evel typing might decrease the risk of GVHD or
raft failure in the double UBC setting. The role of
llele-level typing in double UBC transplantation 1ill need to be clariﬁed as more of these transplants
re performed.
We have demonstrated that the double UBC
ransplantation strategy is an important advance in
dult UBC transplantation. TRM is low, suggesting
hat this approach is an acceptable alternative ap-
roach for patients without sibling donors.
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